Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Gut Microbiome’s Role in Skin Cancer Biology and Treatment Response
Description
The talk explains that the gut microbiome is increasingly recognized as an important factor in cancer biology, prognosis, and treatment response, especially in dermatology and skin cancers. The speaker describes three main ways microbes influence cancer: through microbial metabolites, immune modulation, and effects on therapy response. In melanoma and other skin cancers, altered gut microbiota and microbial products may affect tumor behavior and immunotherapy response. The clearest example is cutaneous T-cell lymphoma (CTCL), where skin and gut dysbiosis appear to actively drive disease rather than simply accompany it. Staphylococcus aureus and its toxins can stimulate malignant T cells, broad-spectrum antibiotics can sometimes reduce disease activity, and microbiome differences may contribute to racial disparities in outcomes. The speaker’s group found that CTCL patients have reduced microbial diversity, fewer beneficial short-chain fatty-acid-producing bacteria, and lower stool levels of metabolites such as propionate and acetate, which normally support immune regulation and epithelial integrity. Overall, the microbiome is presented as a potentially modifiable biomarker and therapeutic target that may help predict outcomes, guide treatment, and perhaps be directly manipulated in future skin cancer care.
View moreConclusions
- The gut microbiome appears to actively shape skin cancer biology rather than merely correlate with it.
- Microbiome-driven changes in metabolites and immune signaling may help determine cancer progression and patient response to therapy.
- In melanoma and other skin cancers, lower microbial diversity and specific bacterial shifts are associated with more advanced disease and worse outcomes.
- Altering the microbiome may improve responsiveness to immunotherapies and other cancer treatments.
- Cutaneous T-cell lymphoma is the clearest example presented of a microbiome-associated skin cancer, with microbes contributing to disease activity, progression, and therapeutic resistance.
- Staphylococcus aureus and its toxins seem to play a particularly important pathogenic role in CTCL.
- Antibiotic treatment and microbiome changes can reduce CTCL activity in at least some patients, supporting a causal role for microbes.
- CTCL patients show gut dysbiosis, including reduced short-chain fatty acid-producing bacteria and lower propionate and acetate levels, which may promote inflammation and tumor permissiveness.
- Microbiome differences may contribute to observed disparities in CTCL outcomes, including higher sepsis risk in Black patients.
- Microbiome profiling may become a clinically useful biomarker and eventually a modifiable therapeutic target in dermatologic oncology.
- Sepich-Poore et al., Science 2021.
- Krohn et al., Allergy 2024.
- Zhou et al., Front in Onc 2022.
- Ma et al., Science 360, 876 (2018).
- Witt et al. JAMA Derm 2023.
- Schor et al., npj Biofilms and Microbiomes 2023.#10.1038/41522.2055-5008
- Bullman et al., Science, 2017.
- Yarchoan et al.
- Baruch et al.
- Zhao et al. Microbiol Spectrum 2025.
- Merlio JP, Blood 2024.
- Lindahl et al Blood 2019
- Vadivel et al, Blood 2024
- Hooper MJ... Zhou XA, Frontiers in Immunology Nov 2022.
- Hooper MJ… Zhou XA, JEADV 2022.
- Thomas ZO...Zhou XA, Arch Derm Res 2025.
- Woo et al. Int. J. Mol. Sci. 2022.